Recommended Antihypertensive for Gout Patients
For patients with gout requiring blood pressure management, losartan or calcium channel blockers are the recommended first-line antihypertensive agents, with losartan being particularly advantageous due to its modest uricosuric effect. 1
Primary Recommendation: Losartan
The 2016 EULAR guidelines explicitly state that when gout occurs in a patient requiring antihypertensive therapy, clinicians should "consider losartan or calcium channel blockers" for hypertension management 1. This recommendation is based on losartan's unique dual benefit:
- Effective blood pressure control as an angiotensin II receptor blocker
- Modest uric acid-lowering effect of approximately 0.3 mg/dL (18-50 μmol/L) through uricosuric action 2, 3, 4
Losartan is the only ARB with proven uric acid-lowering properties 5, 6. While this reduction is substantially smaller than dedicated urate-lowering therapies like allopurinol or febuxostat, it provides meaningful benefit in specific clinical contexts.
Alternative: Calcium Channel Blockers
Calcium channel blockers (both dihydropyridines like amlodipine and non-dihydropyridines like diltiazem) are appropriate alternatives as they have neutral effects on uric acid levels and do not exacerbate hyperuricemia 1.
Critical Medications to AVOID
Thiazide and loop diuretics must be discontinued or substituted if possible in patients with gout 1, 7. These agents:
- Increase serum uric acid levels significantly
- Carry an odds ratio of 1.72 for gout development 7
- Directly counteract gout management efforts
If a diuretic is absolutely necessary (e.g., heart failure), the modest uricosuric effect of losartan may partially offset diuretic-induced uric acid elevation, though this should not replace appropriate urate-lowering therapy in patients with established gout 4.
Clinical Algorithm
Step 1: If patient is on a thiazide or loop diuretic → discontinue if medically feasible 1
Step 2: Select antihypertensive:
- First choice: Losartan (typical dose 50-100 mg daily)
- Second choice: Calcium channel blocker (e.g., amlodipine 5-10 mg daily)
- Avoid: Other ARBs (candesartan, valsartan, azilsartan) as they lack uricosuric properties or may increase uric acid 6
Step 3: Continue appropriate urate-lowering therapy (allopurinol, febuxostat) as indicated—losartan is not sufficient as monotherapy for urate lowering in most gout patients 3
Important Caveats
Losartan's uric acid reduction (~0.3 mg/dL) is clinically meaningful but modest 2, 4. It should be viewed as an advantageous property when selecting among antihypertensives, not as replacement for dedicated urate-lowering therapy in patients with recurrent gout, tophi, or significantly elevated uric acid.
The benefit is most relevant for patients with borderline hyperuricemia, diuretic-associated uric acid elevation, or those at risk for gout 4.
Beta-blockers may increase uric acid levels and should generally be avoided unless specifically indicated for other conditions (e.g., heart failure, post-MI) 3.
ACE inhibitors are not mentioned in gout-specific guidelines as having particular benefit or harm regarding uric acid, making them neutral but less preferable than losartan in this population.